molnupiravir and Respiratory-Insufficiency

molnupiravir has been researched along with Respiratory-Insufficiency* in 1 studies

Other Studies

1 other study(ies) available for molnupiravir and Respiratory-Insufficiency

ArticleYear
Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting.
    Viruses, 2023, 02-23, Volume: 15, Issue:3

    While molnupiravir (MOV) and nirmatrelvir-ritonavir (NMV-r) were developed for treatment of mild to moderate COVID-19 infection, there has been a lack of data on the efficacy among unvaccinated adult patients with chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis. A territory-wide retrospective cohort study was conducted in Hong Kong to investigate the efficacy of MOV and NMV-r against severe outcomes of COVID-19 in unvaccinated adult patients with chronic respiratory diseases. A total of 3267 patients were included. NMV-r was effective in preventing respiratory failure (66.6%; 95% CI, 25.6-85.0%,

    Topics: Adult; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Outpatients; Respiratory Insufficiency; Retrospective Studies; Ritonavir; SARS-CoV-2

2023